Agios Total Current Liabilities vs Total Current Assets Analysis
AGIO Stock | USD 38.17 5.20 11.99% |
Agios Pharm financial indicator trend analysis is way more than just evaluating Agios Pharm prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Agios Pharm is a good investment. Please check the relationship between Agios Pharm Total Current Liabilities and its Total Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
Total Current Liabilities vs Total Current Assets
Total Current Liabilities vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Agios Pharm Total Current Liabilities account and Total Current Assets. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Agios Pharm's Total Current Liabilities and Total Current Assets is 0.5. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Agios Pharm, assuming nothing else is changed. The correlation between historical values of Agios Pharm's Total Current Liabilities and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Agios Pharm are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Current Liabilities i.e., Agios Pharm's Total Current Liabilities and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.5 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Current Liabilities
Total Current Liabilities is an item on Agios Pharm balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Agios Pharm are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Agios Pharm's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Agios Pharm current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.At this time, Agios Pharm's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 13th of December 2024, Enterprise Value is likely to grow to about 1.5 B, while Selling General Administrative is likely to drop about 81.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 836K | 12.8M | 14.7M | 15.4M | Depreciation And Amortization | 18.8M | 18.6M | 6.6M | 8.3M |
Agios Pharm fundamental ratios Correlations
Click cells to compare fundamentals
Agios Pharm Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Agios Pharm fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 890.7M | 853.0M | 1.4B | 1.2B | 937.1M | 752.6M | |
Other Current Liab | 53.1M | 61.9M | 32.0M | 30.4M | 28.2M | 28.5M | |
Total Current Liabilities | 92.9M | 94.4M | 59.8M | 62.6M | 68.0M | 75.2M | |
Total Stockholder Equity | 640.5M | 399.5M | 1.3B | 1.1B | 811.0M | 564.7M | |
Other Liab | 77.4M | 50.6M | 261.3M | 3.3M | 3.8M | 3.6M | |
Property Plant And Equipment Net | 126.1M | 117.5M | 104.2M | 88.1M | 69.8M | 52.5M | |
Net Debt | 32.7M | (22.2M) | (106.0M) | (53.6M) | (16.2M) | (17.0M) | |
Retained Earnings | (1.5B) | (1.8B) | (238.8M) | (470.6M) | (822.6M) | (863.8M) | |
Accounts Payable | 21.9M | 17.7M | 16.7M | 18.6M | 9.8M | 15.1M | |
Cash | 80.9M | 127.4M | 203.1M | 139.3M | 88.2M | 83.8M | |
Non Current Assets Total | 279.0M | 216.3M | 373.5M | 405.9M | 103.3M | 178.4M | |
Non Currrent Assets Other | (279.0M) | 1.1M | 2.9M | 4.0M | 4.1M | 4.3M | |
Cash And Short Term Investments | 564.9M | 670.5M | 1.3B | 1.1B | 776.9M | 637.5M | |
Common Stock Total Equity | 58K | 68K | 69K | 71K | 81.7K | 49.5K | |
Common Stock Shares Outstanding | 60.0M | 69.0M | 60.4M | 54.8M | 55.7M | 48.8M | |
Short Term Investments | 483.9M | 445.5M | 816.9M | 643.9M | 688.7M | 428.3M | |
Liabilities And Stockholders Equity | 890.7M | 853.0M | 1.4B | 1.2B | 937.1M | 752.6M | |
Non Current Liabilities Total | 157.3M | 359.1M | 85.9M | 75.3M | 58.1M | 112.7M | |
Other Current Assets | 24.2M | 49.1M | 39.8M | 39.0M | 35.0M | 22.1M | |
Other Stockholder Equity | 2.2B | 2.2B | 1.5B | 1.6B | 1.6B | 1.2B | |
Total Liab | 250.2M | 453.5M | 145.8M | 137.9M | 126.1M | 187.9M | |
Property Plant And Equipment Gross | 31.5M | 117.5M | 28.9M | 138.2M | 122.0M | 128.1M | |
Total Current Assets | 611.7M | 636.7M | 1.1B | 832.8M | 833.8M | 574.2M | |
Accumulated Other Comprehensive Income | 202K | 105K | (1.2M) | (12.5M) | (441K) | (463.1K) | |
Short Term Debt | 6.9M | 14.8M | 11.2M | 13.7M | 30.0M | 39.8M | |
Common Stock | 58K | 68K | 69K | 71K | 72K | 51.8K | |
Property Plant Equipment | 31.5M | 32.3M | 28.9M | 23.0M | 26.4M | 21.1M | |
Net Tangible Assets | 640.5M | 399.5M | 1.3B | 1.1B | 1.3B | 633.1M | |
Net Receivables | 15.3M | 25.4M | 4.4M | 2.2M | 2.8M | 2.7M | |
Retained Earnings Total Equity | (1.5B) | (1.8B) | (238.8M) | (470.6M) | (423.5M) | (444.7M) | |
Capital Surpluse | 2.2B | 2.2B | 2.3B | 2.4B | 2.7B | 1.7B | |
Inventory | 7.3M | 14.7M | 16.2M | 8.5M | 19.1M | 20.0M | |
Long Term Investments | 152.9M | 97.6M | 266.4M | 313.9M | 29.4M | 28.0M | |
Non Current Liabilities Other | 157.3M | 359.1M | 85.9M | 3.3M | 1.2M | 1.1M | |
Net Invested Capital | 640.5M | 399.5M | 1.3B | 1.1B | 811.0M | 833.9M | |
Net Working Capital | 518.8M | 542.3M | 1.0B | 770.1M | 765.9M | 702.8M |
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving against Agios Stock
0.7 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
0.64 | VALN | Valneva SE ADR | PairCorr |
0.64 | LLY | Eli Lilly | PairCorr |
0.64 | IMAB | I Mab | PairCorr |
0.58 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 10.26 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.